LINDSEY MILLER: Open Payments
NPI 1770173114 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,557 in 190 payments from 24 companies in 2025. Trend: 2023 $2,959 · 2024 $3,203 · 2025 $3,557
Food & beverage: $3,557
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 32 | $754 |
| Viatris Specialty LLC | 32 | $454 |
| GlaxoSmithKline, LLC. | 25 | $324 |
| Grifols USA, LLC | 12 | $284 |
| GENZYME CORPORATION | 11 | $278 |
| Regeneron Healthcare Solutions, Inc. | 9 | $215 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $212 |
| JAZZ PHARMACEUTICALS INC. | 8 | $173 |
| Verona Pharma, Inc. | 10 | $163 |
| United Therapeutics Corporation | 7 | $137 |
Products named: DUPIXENT, YUPELRI, TEZSPIRE, Prolastin-C Liquid, FASENRA, XYWAV, TRELEGY ELLIPTA, Ohtuvayre.
Industry payments across MS — which companies pay providers there.
